This Rare Disease Week, we continue to raise awareness about the need for continued innovation and development for rare diseases. At UCB, we have a fundamental commitment to people living with severe diseases, their caregivers, and their families, to help them to live their best lives. This means innovating to bring differentiated solutions with unique outcomes, offering the best individual experience, and ensuring access to all those who need these solutions in a way which is viable for patients, society, and UCB.
“At UCB, we believe the greatest needs can’t always be measured in numbers. We don’t see patient population sizes, we see people in need,” said Chris Clark, Global Mission Lead. Whether a severe disease impacts many people or a few, our goal is to help provide what patients value so they can achieve their best, whatever that means for them.”
Read more from UCB leaders Chris Clark and Mark Hope on some of the work UCB is doing in rare disease.
And to learn more about some of the rare disease areas where we’re working, check out disease spotlights on Myasthenia Gravis (MG), a chronic, autoimmune, neuromuscular condition where the body’s immune system mistakenly targets the connection between nerves and muscles, and Immune Thrombocytopenia Purpura (ITP), an autoimmune disease that causes an individual’s immune system to attack its’ own platelets.
See these MG and ITP infographics for more info.
Choose Country
- Global Site – English
- Australia – English
- België – Engels
- Belgique – Anglais
- Brasil – Português
- България – Български
- Canada – English
- Canada – Français
- 中国 – 中文
- Česká Republika – Angličtina
- Danmark – Engelsk
- Deutschland – Deutsch
- France – Français
- España – Español
- Ελλάδα – Ελληνικά
- India – English
- Ireland – English
- Italia – Inglese
- 日本 – 日本語
- Казахстан – ағылшын тілі
- 한국 – 한국어
- Luxembourg – Anglais
- Luxemburg – Engels
- Magyarország – Angol
- México & Latinoamérica – Español
- Nederland – Engels
- New Zeeland – English
- Norge – Engelsk
- Österreich – Deutsch
- Polska – Polski
- Portugal – Inglês
- România – Engleză
- Россия – Русский
- Slovensko – Anglický
- Suomi – Englanti
- Sverige – Engelska
- Schweiz – Deutsch
- Suisse – Français
- Türkiye – Türkçe
- Україна – Англійська
- United Kingdom – English
- U.S.A. – English